TG Therapeutics: Briumvi Is Winning. At $54, the Stock Is Betting on a Buyer Nobody Has Named

TG Therapeutics: Briumvi Is Winning. At $54, the Stock Is Betting on a Buyer Nobody Has Named

The same quarter produced both readings. Briumvi's U.S. net revenue hit roughly $228 million, up 64 percent year over year; total revenue rose about 70 percent; and management raised full-year guidance for the second time in six months. There is a respectable argument to buy every number in that sentence. The market instead sold the stock roughly 10 percent the morning after the report, then marked it up about 7 percent this week on takeover chatter that names no buyer.

That is the duel in one week. Both camps are looking at identical books. The bulls see proof that a franchise arrived ahead of schedule. The bears see an expense bill that ate the quarter and a price that now carries a rumor nobody has confirmed. The disagreement is not whether Briumvi is growing. It is what that growth is worth at $54 when a sizable slice of the thesis depends on a bidder who hasn't shown up.

Shared Facts

As of Aug. 22, 2026, intraday, the stock traded at $54.27, up 7.3 percent on the day after a $50.56 close, with an intraday high of $56.87; roughly 5.6 million shares had changed hands by mid-morning, about $305 million of turnover, an enormous tape for a stock this size. The record both camps should sign before the gloves go on:

• Reported. Q2 revenue of $240.3 million, up 70 percent year over year and ahead of the roughly $230–$231 million analysts modeled; Briumvi U.S. net revenue of $227.7 million, up 64 percent; net income of $7.8 million; operating income of $21.7 million; first-half revenue of $445.3 million.
• Reported (GAAP).Per-share earnings of $0.05 against the $0.31–$0.41 the Street modeled — the source of the post-earnings down day.
• Company guidance. Full-year total revenue raised to roughly $950 million; Briumvi U.S. net revenue to $890–$905 million. Management says the drug exits 2026 at about a $1 billion annualized U.S. run rate.
• Reported. Cash, equivalents and investment securities of $612.3 million at June 30 against a $750 million senior secured term loan drawn in March through funds managed by Blue Owl Capital and maturing in 2031. The refinancing was billed as non-dilutive, with room earmarked for opportunistic share repurchases, so the debt did not come at the cost of equity count. Net debt comes to roughly $140 million — my calculation, not a filed line.
• Consensus (Trefis). Roughly $958 million of revenue this year, $1.3 billion next, and about $427 million of non-GAAP net income in 2027.
• Reported (Yahoo).Unconfirmed takeover rumors pointing at a mid-to-large U.S. biopharma. No name, no terms, no process.
• Reported (Trefis).Short interest equal to about 21 percent of basic shares, roughly 13.6 days to cover.

At Thursday's close the market valued TG at about $7.2 billion, near 7.5 times the revenue it now guides for this year. Different data providers disagree on the share count, so sales multiples carry this debate rather than per-share value.

Round 1 — A Franchise or a Launch Ramp?

The bull's strongest case is that Briumvi is no longer a rumor-stage drug but a commercially proven product doing the hardest thing in the category: taking share from the incumbent. It is the fastest-growing anti-CD20 treatment in multiple sclerosis, management reports record demand and a sharp uptick in new patient starts, and the roadmap defends the position rather than hoping it holds — positive results turning the two-dose starting infusion into a single 600 mg infusion on Day 1, a fully enrolled Phase 3 subcutaneous version with quarterly dosing whose topline lands at year-end or early 2027, and an expanding set of uses from myasthenia gravis to treatment-resistant schizophrenia. This is how incumbents get flanked, the bull says: the big drug is Roche's Ocrevus, and the growth now sits with the challenger.

The bear concedes the growth and disputes the word "durable." Briumvi is the third entrant in a winner-heavy class, and the analysts who track the space stress that Briumvi, Novartis's Kesimpta and Roche's subcutaneous Ocrevus are all heightening competition in the dominant anti-CD20 market. The top-20 MS drugs already sold about $20.3 billion in 2024, a mature branded market, not an opening frontier. A 64 percent growth rate is a launch ramp off a low base, and the consensus path itself — roughly $1.3 billion in 2027 versus about $950 million this year — already assumes growth decelerates to roughly 35 percent without help. The bull can show momentum; the bear can show that a slowdown is already being priced.

Winner: the bull, by a short margin. The growth is real and documented, and it outpaces the category. The durability question, though, stays open — nobody can prove in August that a mid-2027 share curve holds.

Round 2 — The Margin Bill

Here the quarter gets embarrassing for one side. Bulls argued the earnings miss was cosmetic, pointing out that the quarter's R&D line swelled to $95.3 million partly because of $54.6 million of subcutaneous-manufacturing start-up costs, with another ~$100 million guided for that effort this year — step-ups that do not recur. Operating income still came in positive at $21.7 million, and a biologic selling north of $1 billion a year is a high-margin engine once the build-out stages pass. Run those levers and the non-GAAP per-share path turns the stock into roughly 17 times 2027 earnings.

The bear reads the same page as a warning. Per-share earnings of $0.05 against modeled $0.31–$0.41 is not a rounding error, and spending moved decisively in the wrong direction: research and development roughly tripled year over year, selling costs rose close to 50 percent, and interest expense more than doubled to $16.6 million on the new term loan. Nothing in the report confirms the operating-expense step-down that the bull's 2027 math requires. If the non-GAAP margin lands near 20 percent instead of 33, the stock is not 17 times next year's earnings — it is closer to 30 times, which is what you pay for a compounding software name, not a single-product MS drug whose confidence just wobbled.

Winner: the bear, and not by a technicality. The price presumes a margin recovery that Q2 evidence moved against. Bulls win the product round; the economics round belongs to the bear.

Round 3 — The Phantom Bid

The bull's answer to all of the above is one word: takeout. A commercial anti-CD20 asset growing 64 percent on a $1 billion run rate is a scarce strategic prize, the argument goes; a buyer receives a marketed drug plus the ENHANCE, subcutaneous, myasthenia gravis and CNS optionality, and the 21 percent short interest turns any confirmed process into a squeeze accelerant. One firm, B. Riley, recently lifted its target to $86 from $55, and even without a deal the Street's mean target sits in the mid-$60s — upside the stand-alone story still supports.

The bear wants the name, the terms, or the process. There are none. An unnamed rumor carries close to zero verifiable probability, yet it is the marginal driver of the current tape — the stock fell 10 percent on the earnings morning and is up again purely on chatter. No rational acquirer needs to bid now, because the meaningful data — full ENHANCE readout, the subcutaneous topline, the myasthenia gravis trial — land within roughly a year of today and would let a buyer de-risk the margin question first. Paying the current price means funding a deal that has not been confirmed on top of a run that had already put shares up near 75 percent by mid-June.

Winner: the bear on evidence, with a real concession to the bull. The option has genuine value; that is precisely why it belongs in the price at a discount, not at face value.

Valuation, or What $54 Demands

Put both stories through the same frame. Roughly $7.2 billion of equity at Thursday's close, plus about $140 million of net debt.

Variable	Shared fact	Bull assumption	Bear assumption	Price-implied
Growth	Q2 U.S. sales +64% y/y	30–40% holds through 2027	Decelerates hard as base grows	~35% to $1.3B in 2027 (consensus)
Margin	Q2 GAAP EPS $0.05	Opex spikes are one-time; ~33% non-GAAP net in 2027	Spend is structural; recovery stalls	~33% non-GAAP net on 2027 consensus
Takeout	Rumor unconfirmed	Named bidder before the data drops	No bidder until de-risked readouts	Partial credit already in the tape

Without a takeout, the current price is a bet on the consensus 2027 path: $1.3 billion of revenue at roughly a 33 percent non-GAAP net margin, which would leave the stock near 17 times 2027 earnings. Move only the margin variable to 20 percent and the same revenue leaves the stock near 30 times earnings — the difference between "growing-priced-right" and "expensive." The whole duel reduces to that one margin assumption, and the freshest evidence on it moved down, not up.

The Ruling

The business case goes to the bull; the stock call at $54 goes to the bear. The product is real, the growth is real, and the balance sheet is funded — nothing here is a fraud or a value trap. But the price now requires the margin recovery the second quarter contradicted and a buyer nobody has named, and it is offering exit liquidity on a rumor that every rational acquirer has reason to wait out. Even the analyst tape is split on direction — one aggregator already scores the nine covering brokers as a Hold — another sign the premium is sentiment, not arithmetic. The burden of proof sits with the bull.

The call reverses on evidence, not headlines, and on a date. Name a bidder or open a formal process and I flip to the bull immediately — the squeeze math alone confirms the direction. Short of that, the tripwire is the subcutaneous topline, expected at year-end 2026 or early 2027, plus the 2027 margin posture: if management guides toward a roughly 30 percent non-GAAP margin while Briumvi keeps printing 50-plus-percent growth, today's premium was pre-paid rather than over-paid, and the ruling changes. The bear's own uncovered flank is exactly that — a growth rate that keeps accelerating while opex flattens. Watch the readout, not the rumor board.